Advancing new therapies for multiple cancers with PAM (PI3K/AKT/mTOR) pathway involvement

Celcuity is a clinical-stage biotechnology company focused on developing a better way to address cellular abnormalities that drive tumor growth. Our teams of drug development scientists, biochemists, and molecular biologists are working to advance new targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway. This pathway plays a critical role as biological driver of a range of tumor types, including breast, prostate, lung, endometrial, colon, and ovary.

Our lead product candidate, gedatolisib, is a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, and/or mTORC1 alone or together. Gedatolisib thus offers hope to meaningfully extend the time that a patient’s tumors are not progressing.

Our Team
Brian Sullivan

Brian Sullivan

CEO and Co-founder
Lance Laing, PhD

Lance Laing, PhD

Chief Science Officer and 
Co-founder
Vicky Hahne

Vicky Hahne

CFO
Igor Gorbatchevsky, MD

Igor Gorbatchevsky, MD

Chief Medical Officer
Eldon Mayer

Eldon Mayer

Chief Commercial Officer
Brent Eilefson

Brent Eilefson

General Counsel
Bernhard Lampert, PhD

Bernhard Lampert, PhD

VP of Pharmaceutical Development
Nadene Zack

Nadene Zack

VP Clinical Operations
Sunni Miller

Sunni Miller

VP of Regulatory Affairs
David Bridge

David Bridge

VP of Quality Assurance and Process Development
Fred Kerwood

Fred Kerwood

VP of Program Management
Board of Directors

Brian Sullivan

CEO and Co-founder

Lance Laing, PhD

Chief Science Officer and 
Co-founder

Richard Buller

MD, PhD, Director

David F. Dalvey

Director

Leo Furcht

MD, Director

Polly Murphy

DVM, PhD, Director

Richard J. Nigon

Director
Scientific Advisory Board

Manfred Auer, PhD

Adam Brufsky, MD, PhD

Edward Greeno, MD

Sara Hurvitz, MD

Benita Katzenellenbogen, PhD

John Katzenellenbogen, PhD

Hung Khong, MD

Carol Lange, PhD

Bora Lim, MD

Stanley Marks, MD

Ron McGlennen, MD

Alberto Montero, MD, MBA, CPHQ

Ben Ho Park, MD, PhD

Mark Pegram, MD, PhD

Mothaffar F. Rimawi, MD

Lee S. Schwartzberg, MD, FACP

Contact

Celcuity Inc.
16305 36th Avenue North
Minneapolis, MN 55446

If you are a healthcare professional and would like to learn more about gedatolisib, our technology, or our current clinical trials, please use the form below to contact us.